Loading…
TRAZODONE HYDROCHLORIDE is a brand name for Trazodone. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Relief of symptoms in all types of depression including depression accompanied by anxiety. Symptoms of depression likely to respond in the first week of treatment include depressed mood, insomnia, anxiety, somatic symptoms and hypochondriasis.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults:
Starting dose is 150mg/day in divided doses after food or as a single dose before retiring. This may be increased to 300mg/day, the major portion of which is preferably taken on retiring. In hospitalised patients, dosage may be further increased to 600mg/day.
Paediatric population:
There are insufficient data on safety to recommend the use of trazodone in children below the age of 18 years. 4). This may be incrementally increased, under supervision, according to efficacy and tolerance. In general, single doses above 100mg should be avoided in these patients.
Doses above 300mg/day are unlikely to be required. A decrease in side-effects (increase of the resorption and decrease of the peak plasma concentration) can be reached by taking trazodone hydrochloride after a meal. In conformity with current psychiatric opinion, it is suggested that trazodone be continued for several months after remission.
Cessation of trazodone treatment should be gradual. 8. Therefore, caution should be exercised when prescribing for patients with hepatic impairment, particularly in cases of severe hepatic impairment. Periodic monitoring of liver function may be considered.
2). Method of administration For oral use.
8. Therefore, caution should be exercised when prescribing for patients with hepatic impairment, particularly in cases of severe hepatic impairment. Periodic monitoring of liver function may be considered. 2). Method of administration For oral use.
1. • Alcohol intoxication and intoxication with hypnotics. • Acute myocardial infarction. 4 Special warnings and precautions for use Use in paediatric population and adolescents under 18 Trazodone should not be used in children and adolescents under 18 years old.
Suicidal behaviour (suicidal attempt and suicidal planning) and hostility (essentially aggressiveness, opposing behaviour and anger) has been observed in a clinical study on children and adolescents treated with antidepressant more frequently than with placebo.
Moreover, long-term safety data on children and adolescents regarding growth, maturation and cognitive and behavioural development are not available. Suicide/suicidal thoughts or clinical worsening Depression is associated with an increased risk of suicidal thoughts, self-harm, and suicide (suicide-related events).
This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Other psychiatric conditions for which trazodone is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.
Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts and should receive careful monitoring during treatment.
Use in paediatric population and adolescents under 18 Trazodone should not be used in children and adolescents under 18 years old. Suicidal behaviour (suicidal attempt and suicidal planning) and hostility (essentially aggressiveness, opposing behaviour and anger) has been observed in a clinical study on children and adolescents treated with antidepressant more frequently than with placebo.
Moreover, long-term safety data on children and adolescents regarding growth, maturation and cognitive and behavioural development are not available. Suicide/suicidal thoughts or clinical worsening Depression is associated with an increased risk of suicidal thoughts, self-harm, and suicide (suicide-related events).
This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Other psychiatric conditions for which trazodone is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.
Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts and should receive careful monitoring during treatment.
A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
1. • Alcohol intoxication and intoxication with hypnotics. • Acute myocardial infarction.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Trazodone in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
To minimise the potential risk of suicide attempts, particularly at therapy initiation, only restricted quantities of trazodone should be prescribed on each occasion. It is recommended that careful dosing and regular monitoring is adopted in patients with the following conditions: • Epilepsy, specifically abrupt increases or decreases of dosage should be avoided • Patients with hepatic or renal impairment, particularly if severe • Patients with cardiac disease, such as angina pectoris, conduction disorders or atrioventricular (AV) blocks of different degree, recent myocardial infarction • Hyperthyroidism • Micturition disorders, such as prostate hypertrophy, although problems would not be anticipated as the anticholinergic effect of trazodone is only minor • Acute narrow angle glaucoma, raised intra-ocular pressure, although major changes would not be anticipated due to the minor anticholinergic effect of trazodone Should jaundice occur in a patient, trazodone therapy must be withdrawn.
8). Patients should be instructed to report immediately signs such as asthenia, anorexia, nausea, vomiting, abdominal pain, or icterus to a physician. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately, and withdrawal of trazodone therapy be considered.
Administration of antidepressants in patients with schizophrenia or other psychotic disorders may result in a possible worsening of psychotic symptoms. Paranoid thoughts may be intensified. During therapy with trazodone a depressive phase can change from a manic– depressive psychosis into a manic phase.
In that case trazodone must be stopped. g. tricyclic antidepressants, SSRI’s, SNRI’s and MAOinhibitors) and neuroleptics. 8 for further information. Since agranulocytosis may clinically reveal itself with influenza-like symptoms, sore throat, and fever, in these cases it is recommended to check haematology.
Hypotension, including orthostatic hypotension and syncope, has been reported to occur in patients receiving trazodone. Concomitant administration of antihypertensive therapy with trazodone may require a reduction in the dose of the antihypertensive drug.
Elderly patients may more often experience orthostatic hypotension, somnolence, and other anticholinergic effects of trazodone more often. Careful consideration should be given to the potential for additive effects with concomitant medication use such as with other psychotropics or […]
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
To minimise the potential risk of suicide attempts, particularly at therapy initiation, only restricted quantities of trazodone should be prescribed on each occasion. It is recommended that careful dosing and regular monitoring is adopted in patients with the following conditions: • Epilepsy, specifically abrupt increases or decreases of dosage should be avoided • Patients with hepatic or renal impairment, particularly if severe • Patients with cardiac disease, such as angina pectoris, conduction disorders or atrioventricular (AV) blocks of different degree, recent myocardial infarction • Hyperthyroidism • Micturition disorders, such as prostate hypertrophy, although problems would not be anticipated as the anticholinergic effect of trazodone is only minor • Acute narrow angle glaucoma, raised intra-ocular pressure, although major changes would not be anticipated due to the minor anticholinergic effect of trazodone Should jaundice occur in a patient, trazodone therapy must be withdrawn.
8). Patients should be instructed to report immediately signs such as asthenia, anorexia, nausea, vomiting, abdominal pain, or icterus to a physician. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately, and withdrawal of trazodone therapy be considered.
Administration of antidepressants in patients with schizophrenia or other psychotic disorders may result in a possible worsening of psychotic symptoms. Paranoid thoughts may be intensified. During therapy with trazodone a depressive phase can change from a manic– depressive psychosis into a manic phase.
In that case trazodone must be stopped. g. tricyclic antidepressants, SSRI’s, SNRI’s and MAOinhibitors) and neuroleptics. 8 for further information. Since agranulocytosis may clinically reveal itself with influenza-like symptoms, sore throat, and fever, in these cases it is recommended to check haematology.
Hypotension, including orthostatic hypotension and syncope, has been reported to occur in patients receiving trazodone. Concomitant administration of antihypertensive therapy with trazodone may require a reduction in the dose of the antihypertensive drug.
Elderly patients may more often experience orthostatic hypotension, somnolence, and other anticholinergic effects of trazodone more often. Careful consideration should be given to the potential for additive effects with concomitant medication use such as with other psychotropics or antihypertensives or in the presence of risk factors such as comorbid disease, which may exacerbate these reactions.
It is recommended that the patient/carer is informed of the potential for these reactions and monitored closely for such effects following initiation of therapy, prior to and following upward dose titration. Following therapy with trazodone, particularly for a prolonged period, an incremental dosage reduction to withdrawal is recommended, to minimise the occurrence of withdrawal symptoms, characterised by nausea, headache, and malaise.
There is no evidence that trazodone hydrochloride possesses any addictive properties. As with other antidepressant drugs, cases […]